ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 17, 2025

Primary Completion Date

January 8, 2027

Study Completion Date

November 2, 2027

Conditions
Acromegaly
Interventions
DRUG

ALXN2420

ALXN2420 will be administered via subcutaneous (SC) injection

DRUG

Placebo

Placebo will be administered via SC injection.

Trial Locations (43)

1083

Research Site, Budapest

1134

Research Site, Budapest

2100

Research Site, Copenhagen

5464

Research Site, Odense

6725

Research Site, Szeged

7624

Research Site, Pécs

10032

Research Site, New York

16132

Research Site, Genoa

20132

Research Site, Milan

44124

Research Site, Cona

48109

Research Site, Ann Arbor

56126

Research Site, Pisa

80131

Research Site, Napoli

89148

Research Site, Las Vegas

90048

Research Site, Los Angeles

90095

Research Site, Los Angeles

90502

Research Site, Torrance

97239

Research Site, Portland

98125

Research Site, Messina

100730

Research Site, Beijing

201107

Research Site, Shanghai

400006

Research Site, Cluj-Napoca

510120

Research Site, Guangzhou

650032

Research Site, Kunming

02114

Research Site, Boston

C1180AAD

Research Site, Buenos Aires

C1405DCS

Research Site, Buenos Aires

C1012AAR

Research Site, CABA

C1199

Research Site, Ciudad de Buenos Aires

80030-110

Research Site, Curitiba

14049-901

Research Site, Ribeirão Preto

20231-092

Research Site, Rio de Janeiro

01420-000

Research Site, São Paulo

00168

Research Site, Roma

LT50009

Research Site, Kaunas

09112

Research Site, Vilnius

2333 ZA

Research Site, Leiden

3015 CE

Research Site, Rotterdam

44-102

Research Site, Gliwice

31-501

Research Site, Krakow

03-242

Research Site, Warsaw

50-367

Research Site, Wroclaw

011863

Research Site, Bucharest

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY